Automatically clustered newsroom coverage around one of the most active themes in the intellectual property ecosystem.
Actinium Pharmaceuticals has announced significant intellectual property advancements for its Actimab-A targeted radiotherapy program, including the issuance of new U.S. patents covering treatment of solid tumors and acute myeloid leukemia (AML). The company also expanded its manufacturing capabilities by adding a new…
Nuclea Energy has acquired 89 current and pending patents from Moltex Energy, a New Brunswick nuclear developer whose British parent company went into administration in 2023. The transaction, valued at approximately $11.5 million according to a prior Nuclea filing, enhances Nuclea’s technology capabilities as it devel…
Femasys Inc. has secured multiple patents across key global markets covering the blended polymer component of FemBloc, its non-surgical permanent birth control solution. These patents complement existing delivery system patents, broadening FemBloc’s intellectual property protection as the company advances its pivotal…
Beren Therapeutics has secured eight additional U.S. patents related to its proprietary cyclodextrin-based therapeutics, including adrabetadex, enhancing its intellectual property estate. These patents cover compositions, pharmaceutical formulations, manufacturing processes, and methods of treatment for Niemann-Pick d…
American Fusion Inc. (OTC: AMFN) has filed six additional U.S. patent applications, increasing its total to 82, as it progresses the development and regulatory initiatives of its Texatron™ Fusion Engine™. The new filings cover innovations in fusion reactor architecture, plasma confinement, and control systems. Concurr…
On August 3, 2026, Decoy Therapeutics announced a significant expansion of its intellectual property portfolio, now encompassing seven patent families with 19 pending applications across the U.S., Australia, Canada, China, Europe, Japan, and New Zealand. The portfolio protects its Designable Multi-Antivirals (D-MAVs™)…
Decoy Therapeutics Inc. has expanded its intellectual property holdings to encompass seven patent families and 19 pending applications worldwide. The portfolio safeguards antiviral peptide conjugates, manufacturing methods, formulations, and the IMP³ACT™ design platform that underpins its Designable Multi-Antivirals (…
Vector Science & Therapeutics Corp. has expanded its intellectual property holdings to include 15 patent applications filed over the past two years. These applications cover a wide array of technologies aimed at enhancing precision delivery of therapeutic agents, particularly peptides and biologics, via non-invasive,…
Vector Science & Therapeutics has developed a comprehensive intellectual property portfolio comprising 15 patent applications over two years. The portfolio centers on innovative delivery systems for peptides and biologics, addressing challenges in targeted therapeutic administration across pain management, oncology, r…
Elektros Inc. has updated shareholders on its intellectual property efforts surrounding U.S. Patent No. 12,522,100, a multi-port charging assembly for electric vehicles. The company recently received acknowledgment from Volkswagen Group of America regarding its patented technology, signaling ongoing patent review disc…
UPM has acquired the intellectual property rights to Avantium’s Ray Technology®, a process for producing bio-based mono-ethylene glycol (MEG) and mono-propylene glycol (MPG) from plant sugars. This strategic move broadens UPM’s IP portfolio in bio-based glycols, reinforcing its position as a leader in renewable chemic…
Subscribe to receive daily and weekly newsroom coverage aligned to this trend cluster and adjacent IP developments.